
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **April 1, 2011 (March 31, 2011)**

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-16133
(Commission File Number)

06-1245881
(IRS Employer
Identification Number)

810 Seventh Avenue, Suite 3505, New York, New York, 10019
(Address of principal executive offices, including zip code)

(212) 489-2100
(Registrant's telephone number, including area code)

NONE
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 31, 2011, Delcath Systems, Inc. (the “Company”) announced that it had increased the size of its Board of Directors from seven to eight and appointed Gabriel Leung, M.Sc. to fill this new vacancy, effective March 30, 2011 (the “Effective Date”). Mr. Leung will serve as a Class III director with a term expiring at the Company’s 2012 annual stockholder meeting. At the present time, Mr. Leung has not been assigned to any committees of the Company’s Board of Directors. Mr. Leung will receive standard director fees and benefits, including an initial grant of stock options under the Company’s 2009 Stock Incentive Plan (the “Plan”) to purchase \$75,000 worth of shares of the Company’s common stock, vesting in three installments over three years, at an exercise price per share equal to the fair market value thereof on the Effective Date determined in accordance with the Plan.

On March 31, 2011, the Company issued a press release announcing the foregoing matters, a copy of which is filed as Exhibit 99.1 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits.

The following exhibit is filed herewith:

(d) Exhibits.

Exhibit No.	Description
--------------------	--------------------

99.1	Delcath Systems, Inc. Press Release dated March 31, 2011
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELCATH SYSTEMS, INC.

Dated: April 1, 2011

By: /s/ Barbra Keck
Name: Barbra Keck
Title: Vice President, Controller

EXHIBIT INDEX

Exhibit No.	Description
99.1	Delcath Systems, Inc. Press Release dated March 31, 2011



**DELCATH EXPANDS BOARD OF DIRECTORS
WITH APPOINTMENT OF GABRIEL LEUNG**

New York, NY – March 31, 2011 -- Delcath Systems, Inc. (NASDAQ: DCTH), a development stage, specialty pharmaceutical and medical device company focused on oncology, announced today the appointment of Gabriel Leung, M.Sc. to the Company's expanded Board of Directors, effective immediately. The Company increased the size of its Board of Directors from seven to eight and appointed Mr. Leung to fill this new vacancy. Mr. Leung will serve as a Class III director with a term expiring at the 2012 annual stockholder meeting.

With more than 20 years in the oncology pharmaceuticals marketplace and broad scientific expertise, Mr. Leung brings a wealth of experience in successfully gaining regulatory approval for and launching oncology drugs. Mr. Leung most recently served as President of the Pharmaceuticals Business at OSI Pharmaceuticals, overseeing its oncology, diabetes and obesity businesses prior to the Company's acquisition by Astellas Pharma Inc. in June 2010. During his seven years at OSI, Mr. Leung held several senior management positions, led the successful filing of two supplemental New Drug Applications (NDA) for Tarceva® (erlotinib) and guided it to the most successful launch in U.S. oncology history with global sales exceeding \$1.2 billion in 2009. During this time, OSI's market capitalization increased from \$1.4 billion to approximately \$4.0 billion at the time of acquisition.

Prior to OSI, Mr. Leung served as Group Vice President, Global Prescription Business & Head of the Global Oncology Franchise for Pharmacia Corporation. At Pharmacia, Mr. Leung served on the CEO's Corporate Operating Committee, overseeing all oncology clinical development projects and discovery portfolio strategy that led to four successful ODAC panel recommendations and NDA/sNDA approvals. Previously, Mr. Leung held several leadership positions at Bristol-Myers Squibb. Currently, Mr. Leung serves on the Board of Directors of Albany Molecular Research, Inc., a company focused on drug discovery and development projects as well as the manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. He has also previously served on the Board of Directors of NanoMed, Inc. Mr. Leung holds a BS in Pharmacy with high honors from the University of Texas, and an MS in Pharmacy from the University of Wisconsin.

Commenting on the announcement, Dr. Harold S. Koplewicz, Chairman of Delcath's Board of Directors, said, "We are very pleased to welcome Gabriel Leung to our board. His strong pharmaceutical business and scientific background, industry relationships and established track record of helping to increase shareholder value will be invaluable as Delcath transitions from a development stage company to a commercial organization."

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, acceptance of the Company's CE Mark Technical File by its Notified Body, receipt of CE Mark approval, adoption, use and resulting sales in the EU, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, approval of the current or future chemosaturation system for other indications, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Investor Contact:
Gregory Gin/Doug Sherk
EVC Group
646-455-4801/415-896-6818

Media Contact:
Janine McCargo
EVC Group
646-528-4034
